{"brief_title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.", "brief_summary": "This study will evaluate the safety and tolerability of PEGASYS plus ribavirin in previous intravenous (iv) drug users who have CHC and are currently enrolled in a methadone maintenance treatment program. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals.", "condition": ["Hepatitis C, Chronic"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["peginterferon alfa-2a [Pegasys]", "ribavirin"], "description": ["180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)", "1000/1200mg (< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)"], "arm_group_label": ["Direct Observed Therapy", "Self-Administration Therapy", "Direct Observed Therapy", "Self-Administration Therapy"], "criteria": "Inclusion Criteria: - adult patients at least 18 years of age - CHC infection, genotype 1, 2, or 3 - naive to treatment for CHC infection - enrolled in a methadone maintenance program with documented attendance for at least 3 months - use of 2 forms of contraception during the study on both men and women Exclusion Criteria: - previous treatment for CHC infection - co-infection with human immunodeficiency virus (HIV) - current use of IV or other illicit drugs - decompensated cirrhosis - women who are pregnant or breastfeeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Hepatitis", "Hepatitis C", "Hepatitis C, Chronic", "Ribavirin", "Peginterferon alfa-2a", "Interferon-alpha", "Methadone"], "id": "NCT00087594"}